Drugs / Lactobacillus Crispatus M247
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05808816 | Jun 2021 → Feb 2023 | bacterial vaginosis, cervical adenosquamous carcinoma, cervical squamous intraepithelial neoplasia, human papilloma virus infection | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06978907 | Jul → Nov 2025 | vulvovaginitis | Liaquat University of Medical & Health Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus Crispatus M247 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05808816 ↗ |
| Known as | Crispact | “Lactobacillus crispatus M247 (Crispact®), a probiotic containing 20 billion CFU” NCT06978907 ↗ |
| Route | Oral | “Oral supplementation of Lactobacillus Crispatus M247 in patients with cervical low grade lesions HPV related” NCT05808816 ↗ |